Nkarta Q3 2026 Results: Net Loss of $33.3M, Loss Widens
Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on CAR NK-cell therapies, specifically NKX019 for autoimmune diseases. As of September 30, 2026, the company remains pre-revenue with significant accumulated losses and expects to continue incurring losses as it advances its novel therapeutic platform through clinical development.
- Key figure
- Net loss $33.3M